RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The initiative aims to connect startups and tech companies with its business units,
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Subscribe To Our Newsletter & Stay Updated
